GlassScriptPhysician profile
Neeraja Tandra
NPI 1821201385
$69,617.75
in general payments reported to CMS, 2019-2025
27 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $158 · 2021: $339 · 2022: $4,117 · 2023: $17K · 2024: $25K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $40K · Consulting Fee: $10K · Travel and Lodging: $10K · Food and Beverage: $4,213 · Education: $66.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $39,750.00 |
| Consulting Fee | $10,356.00 |
| Travel and Lodging | $10,194.03 |
| Food and Beverage | $4,212.77 |
| Education | $66.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $49,651.98 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $5,968.64 | 2022-2025 | |
| Scpharmaceuticals INC. | $5,181.50 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,115.69 | 2025 | |
| Mallinckrodt Hospital Products INC. | $598.14 | 2020-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $456.34 | 2021-2023 | Ultomiris |
| Novo Nordisk INC | $447.02 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $306.84 | 2019-2025 | |
| Akebia Therapeutics INC | $248.71 | 2020-2025 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $225.50 | 2019-2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $212.42 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $211.80 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $169.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $142.33 | 2019-2025 | Farxiga |
| Abbvie INC. | $113.91 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $100.12 | 2019 | |
| Cardiovascular Systems INC. | $94.74 | 2022 | |
| Amgen INC. | $69.35 | 2023-2025 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $65.41 | 2023-2024 | Benlysta, Nucala, Jesduvroq |
| Ani Pharmaceuticals, INC. | $57.48 | 2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $39.98 | 2019-2023 | Rayaldee |
| Recor Medical INC | $33.25 | 2025 | Paradise Ultrasound Renal Denervation System |
| Janssen Pharmaceuticals, INC | $32.68 | 2019 | |
| Genentech USA, INC. | $28.02 | 2025 | Gazyva |
| Lilly USA, LLC | $17.33 | 2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $16.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraja Tandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.